Francis Cano - Aug 8, 2022 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Director
Signature
Francis R. Cano, Ph.D., by /s/ Trevor Dutcher, Attorney-in-Fact
Stock symbol
DVAX
Transactions as of
Aug 8, 2022
Transactions value $
-$183,000
Form type
4
Date filed
8/10/2022, 08:21 PM
Previous filing
May 27, 2022
Next filing
May 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Options Exercise $74.6K +15K +72% $4.97 35.8K Aug 8, 2022 Direct
transaction DVAX Common Stock Sale -$258K -15K -41.86% $17.17 20.8K Aug 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Stock Option (Right to Buy) Options Exercise -15K -100% 0 Aug 8, 2022 Common Stock 15K $4.97 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $17.16 to $17.20; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F2 These options fully-vested on May 30, 2020, upon the one-year anniversary of the grant date.
F3 Not applicable.